diethylnitrosamine has been researched along with telmisartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelnasser, A; Abdo, WS; Basuony, M; Eldin, AS; Elsaeed, B; Khodir, AE; Mahmoud, M; Medhat, R; Megahed, N; Nader, K; Saber, S; Salama, MM; Shawky, A; Soliman, WE | 1 |
| El-Gizawy, SA; Essa, EA; Kira, AY; Nasr, M; Saber, S | 1 |
2 other study(ies) available for diethylnitrosamine and telmisartan
| Article | Year |
|---|---|
Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Diethylnitrosamine; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 2; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; PPAR gamma; Telmisartan; Transcription Factor RelA; Vascular Endothelial Growth Factor A | 2019 |
Lactosylated Chitosan Nanoparticles Potentiate the Anticancer Effects of Telmisartan In Vitro and in a
Topics: Animals; Carcinoma, Hepatocellular; Chitosan; Diethylnitrosamine; Hep G2 Cells; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Mice; Nanoparticles; Telmisartan; Tissue Distribution; Vascular Endothelial Growth Factor A | 2023 |